Article Text

PDF
Continued use of antipsychotic drugs increased long-term mortality in patients with Alzheimer diseaseCommentary

Statistics from Altmetric.com

STUDY DESIGN

Design:

randomised placebo-controlled trial (DART-AD). ISRCTN33368770.

Allocation:

concealed.*

Blinding:

blinded {patients, caregivers and relatives, clinicians, people administering trial drugs, and outcome assessors}†.*

STUDY QUESTION

Setting:

nursing or residential care facilities in the UK.

Patients:

165 patients (mean age 85 y, 76% women) who lived in nursing or residential homes, had possible or probable Alzheimer disease (AD, National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer’s Disease and Related Disorders Association criteria) and a Mini-Mental State Examination score >6 or Severe Impairment Battery score >30, and were taking antipsychotic drugs (APDs) for ⩾3 months for behavioural or psychiatric disturbance (risperidone, ⩾0.5 mg/d or ⩾10 mg of chlorpromazine or equivalent of thioridazine, haloperidol, or trifluoperazine). Exclusion criteria were inability to take capsules or complete baseline …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.